Study Focuses on Molecular Changes Associated With Different Kinds of Endometriosis Pain

Brigham gynecologist and clinical oncologist Naoko Sasamoto, MD, PhD, MPH, is focused on developing novel therapeutics that target the underlying causes of endometriosis, a disease that affects up to 10% of women of reproductive age and causes pelvic pain that can severely impact a patient’s quality of life.

Read More...

Three Studies Find Statins Protect Against Cardiovascular Disease in High-Risk Groups

Brigham researchers are challenging the trend of deprescribing statins in people over 75 years of age. Ariela Orkaby, MD, MPH, led a trio of studies of statin use in older adults with chronic kidney disease, older adults with and without frailty, and adults with heart failure with preserved ejection fraction.

Read More...

Effects of Modafinil on Cognition and Sleep Quality in Affectively Stable Patients With Bipolar Disorder

Brigham researchers suggest modafinil may have a positive impact on neurocognitive functioning and possibly daytime sleepiness, but it may also have a negative effect on sleep quality.

Read More...

Meet Anthony D’Amico, MD, PhD

Anthony D'Amico MD, PhD

Meet Anthony D’Amico, MD, PhD, Chief of Genitourinary Radiation Oncology at Dana-Farber Brigham Cancer Center, and Eleanor Theresa Walters Distinguished Chair in Radiation Oncology, renowned for his exceptional contributions to cancer care, particularly in genitourinary cancer.

Read More...

Patients With EGFR-Mutant NSCLC May Benefit from Targeted Therapy More Than Checkpoint Inhibitors

An estimated 10 to 15% of non-small cell lung cancers harbor EGFR mutations.

A recent retrospective, multicenter cohort study suggests osimertinib is more likely to benefit non-small cell lung cancer patients with EGFR mutations than alternative approaches, though prospective clinical trials are needed to confirm the findings. The Brigham’s Elio Adib, MD, a co-author of the study, discusses key takeaways.

Read More...

Proof of Concept: Presenilin-based Gene Therapy Targets Early-onset Alzheimer’s Disease Carrying PSEN Mutations

Mutations in human presenilin genes (PSEN1 and PSEN2) are the major cause of early-onset familial Alzheimer’s disease (FAD). Building on the previous work, Brigham reserachers have published preclinical evidence that using gene therapy to deliver a functional copy of PSEN1 may someday be able to treat FAD.

Read More...

New Method of Identifying Disease-associated Traits Could Lead to Better Targeted Therapeutics

Brigham researchers have developed a method for identifying hidden genetic contributors to disease by applying various stress tests to human blood cells. The evoked cellular response traits they observed pinpointed genes and pathways relevant to multiple cardiometabolic and inflammatory diseases.

Read More...

AAN 2024: Brigham Neurologists Share Latest Research

The American Academy of Neurology (AAN) will hosts its 2024 annual meeting on April 13 – 18 in Denver, CO and virtually. Faculty from the Department of Neurology at Brigham and Women’s Hospital will join thousands of international colleagues in presenting their latest research at AAN 2024.

Read More...

What Prompts Bariatric Surgery Patients to Seek Care Again?

Brigham researchers conducted a first-of-its-kind retrospective study to better understand the subset of bariatric surgery patients who do not comply with recommended follow-ups that would help optimize long-term outcomes. Ali Tavakkoli, MD, chief of the Division of General and GI Surgery, discusses their findings.

Read More...

Combination of SGLT2i, GLP-1 RA, and Non-Steroidal MRA Proposed for Patients With Type 2 Diabetes and Albuminuria

After analyzing data from pivotal trials, researchers at Brigham and Women’s Hospital believe treatment with a combination SGLT2i, GLP-1 RA, and nonsteroidal MRA has the potential to improve survival in patients with type 2 diabetes and at least moderately increased albuminuria.

Read More...